MK 0759
Alternative Names: MK-0759Latest Information Update: 18 Mar 2010
At a glance
- Originator Merck & Co
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Postherpetic neuralgia
Most Recent Events
- 01 Oct 2005 Phase-II clinical trials in Postherpetic neuralgia in USA (unspecified route)